Loading…
Provides gene synthesis, molecular biology tools and contract research services to biotech and pharma; also holds a stake in CAR-T therapy maker Legend Biotech.
Provides gene synthesis, molecular biology tools and contract research services to biotech and pharma; also holds a stake in CAR-T therapy maker Legend Biotech.
Sells made-to-order DNA and gene products and research reagents to labs, with fast turnaround as the selling point, and is paid project by project for contract development work for drugmakers. Its stake in Legend Biotech links it to the CAR-T therapy Carvykti, which Legend markets with Johnson & Johnson.
In one line: A Chinese Twist Bioscience/Thermo Fisher tools business, plus a biotech stake.
Moat: narrow (scale, process know-how). Large-scale, fast-turnaround gene synthesis capacity built over years gives a service-speed edge.
Headquarters: Nanjing, China · Founded: 2002 · Employees: 6,165
Size Genscript Biotech (1548.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $8.81B, the 175th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$30.38 on 6 Nov 2026.
Performance Over six months the shares gained 96.2%, against +9.0% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 53.5% over the last twelve months (peer median +25.2%); the operating margin is 12.3% (peer median 9.4%).
Valuation It trades at 297.9× forward earnings against a peer median of 35.3× (most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.4 points below its cost of capital (7.9% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$6.60B | HK$7.48B | HK$4.68B | HK$4.37B | HK$4.90B |
| Revenue growth | — | +60% | +7% | -11% | — |
| Gross profit | HK$3.43B | HK$4.31B | HK$2.16B | HK$2.10B | HK$2.38B |
| EBITDA | HK$1.43B | HK$2.57B | HK$589M | HK$616M | -HK$2.90B |
| Net income | -HK$4.97B | -HK$4.15B | -HK$2.11B | -HK$747M | -HK$1.78B |
| Free cash flow | HK$529M | HK$1.98B | -HK$485M | -HK$3.42B | -HK$2.53B |
| Capital expenditure | HK$727M | HK$654M | HK$1.15B | HK$1.23B | HK$1.59B |
| Total debt | n/a | HK$4.74B | HK$1.33B | HK$3.26B | HK$2.74B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Genscript Biotech 1548.HK | $8.81B | +96% | +53% | 12% | 297.9× | 36.5% |
| Twist Bioscience TWST | $7.95B | +112% | +19% | -32% | n/a | n/a |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Danaher DHR | $162B | +35% | +6% | 21% | 25.3× | 20.5% |
| Azenta AZTA | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% |
| Eurofins Scientific ERF.PA | $17.5B | +49% | +3% | 12% | 23.0× | 13.3% |
| Wuxi Bio 2269.HK | $25.0B | +43% | +22% | 32% | 28.7× | 21.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1548.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.2% | -3.0% | lowest of 21 |
| 6-month return | +96.2% | +9.0% | 4th highest of 21 |
| Distance from 52-week high | -38.6% | -23.3% | 7th lowest of 21 |
| Revenue growth (TTM) | +53.5% | +25.2% | 6th highest of 16 |
| Operating margin | 12.3% | 9.4% | 8th highest of 16 |
| Forward P/E | 297.9× | 35.3× | most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 36.5% | 15.3% | 2nd most demanding of 11 |
| Growth delivered (Del g) | +19.8% | +14.3% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | +16.7 pp | -7.1 pp | 4th most demanding of 11 |
| ROIC minus cost of capital | -5.4 pp | -0.7 pp | 7th lowest of 15 |
| EV / EBITDA | 45.5× | 15.8× | most expensive of 8 |
| Net debt / EBITDA | -2.7× | 0.1× | 2nd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 297.9× | 36.5% | +19.8% |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 34.7× | 11.9% | +26.0% |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | n/a | n/a | n/a |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | n/a | 41.8% | +16.6% |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 47.0× | 29.8% | +38.5% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 37.3× | 7.2% | +2.3% |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 10.3× | 6.5% | +12.0% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 86.1× | 18.7% | +85.4% |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 75.5× | n/a | n/a |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | n/a | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 35.9× | 31.3% | +5.5% |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | n/a | n/a | n/a |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 10.7× | 2.5% | +39.2% |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% | +0.1% |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $12.9B | +9% | +12% | 7% | 21.8× | 34.8% | +7.6% |
| Summit Therapeutics SMMT | United States | $13.1B | -10% | n/a | n/a | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |